MSFT 430.59 0.8407% AAPL 222.5 -0.1212% NVDA 119.1 -0.0336% GOOGL 157.46 1.7907% GOOG 158.37 1.8195% AMZN 186.49 -0.2727% META 524.62 -0.1865% AVGO 167.69 1.902% TSLA 230.29 0.2089% TSM 172.5 0.6242% LLY 923.71 -1.2096% V 287.35 0.6938% JPM 204.32 -1.1036% UNH 594.32 1.0027% NVO 137.0 0.2488% WMT 80.6 1.18% LVMUY 134.665 -0.226% XOM 111.15 -0.0719% LVMHF 675.14 0.1691% MA 493.36 0.254%
Last update at 2024-09-13T13:30:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -32.78000M | -30.03097M | -30.77958M | -15.33977M | -16.84569M |
| Minority interest | - | - | - | -0.37504M | -0.08965M |
| Net income | -32.78200M | -30.03097M | -30.77958M | -15.05438M | -16.75604M |
| Selling general administrative | 6.21M | 4.35M | 3.26M | 5.64M | 10.84M |
| Selling and marketing expenses | 1.68M | 5.84M | 0.99M | 0.70M | 1.23M |
| Gross profit | 0.29M | -0.40061M | -3.88241M | 2.13M | 0.22M |
| Reconciled depreciation | 1.95M | 0.27M | 0.35M | 0.40M | 0.04M |
| Ebit | -19.56700M | -28.32464M | -16.83928M | -10.20882M | -15.98764M |
| Ebitda | -17.61800M | -28.05849M | -16.48685M | -9.80716M | -15.94892M |
| Depreciation and amortization | 1.95M | 0.27M | 0.35M | 0.40M | 0.04M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -19.56700M | -28.32464M | -16.83928M | -10.20882M | -15.98764M |
| Other operating expenses | 27.88M | 34.57M | 16.82M | 13.80M | 16.77M |
| Interest expense | 0.69M | 1.71M | 9.27M | 2.09M | 0.43M |
| Tax provision | 0.00200M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.08M | 0.00000M | 0.00032M | 0.06M | 0.14M |
| Net interest income | -0.60800M | -1.70633M | -9.26856M | -2.03292M | -0.28818M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.00200M | 1.73M | 6.80M | 1.71M | 0.41M |
| Total revenue | 8.69M | 6.22M | 2.45M | 3.63M | 0.58M |
| Total operating expenses | 19.48M | 27.95M | 10.49M | 12.30M | 16.42M |
| Cost of revenue | 8.40M | 6.62M | 6.33M | 1.50M | 0.35M |
| Total other income expense net | -12.98000M | 0.03M | -7.14269M | -3.13194M | -0.36287M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -32.78200M | -30.03097M | -30.77958M | -15.33977M | -16.84569M |
| Net income applicable to common shares | -32.78200M | -30.03097M | -30.77958M | -15.05438M | -16.75604M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 37.98M | 29.31M | 19.12M | 22.66M | 22.28M |
| Intangible assets | 15.85M | 8.31M | 1.28M | 4.48M | 4.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2.15M | 0.69M | 0.34M | 0.86M | 0.50M |
| Total liab | 15.69M | 1.56M | 5.47M | 5.39M | 5.78M |
| Total stockholder equity | 22.29M | 27.76M | 13.65M | 17.65M | 16.59M |
| Deferred long term liab | - | - | - | - | 0.61M |
| Other current liab | 0.38M | 1.27M | 0.05M | 1.13M | 0.03M |
| Common stock | 128.38M | 109.95M | 71.79M | 46.53M | 38.22M |
| Capital stock | 128.38M | 109.95M | 71.79M | 46.53M | 38.22M |
| Retained earnings | -126.59800M | -94.82341M | -82.00048M | -51.48230M | -36.42792M |
| Other liab | - | - | - | 0.38M | - |
| Good will | - | - | - | - | - |
| Other assets | 2.43M | 0.42M | - | - | 0.61M |
| Cash | 1.39M | 7.18M | 6.05M | 2.80M | 6.39M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 15.69M | 1.56M | 5.47M | 5.39M | 5.78M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 5.28M | -7.18440M | -2.79134M | 0.43M | -3.61409M |
| Short term debt | 6.67M | - | 3.26M | 3.23M | 2.78M |
| Short long term debt | 6.67M | - | 3.26M | 3.23M | 2.78M |
| Short long term debt total | 6.67M | - | 3.26M | 3.23M | 2.78M |
| Other stockholder equity | 20.51M | 12.63M | 23.86M | 22.60M | 14.80M |
| Property plant equipment | 9.98M | 10.44M | 9.91M | 11.27M | 9.90M |
| Total current assets | 11.87M | 10.14M | 7.94M | 6.92M | 8.28M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 6.45M | 19.44M | 12.38M | 12.80M | 12.49M |
| Short term investments | - | - | - | - | - |
| Net receivables | 2.56M | 1.10M | 0.64M | 1.70M | 0.95M |
| Long term debt | - | - | - | - | - |
| Inventory | 5.77M | 1.86M | 1.25M | 2.42M | 0.44M |
| Accounts payable | 8.64M | 0.28M | 2.16M | 1.03M | 2.97M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 20.51M | 12.63M | 23.86M | 22.60M | 14.80M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.29M | 0.42M | - | 15.75M | -0.00000M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 26.11M | 19.17M | 11.18M | 15.75M | 14.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2.28400M | -1.37146M | -0.40254M | -0.40254M | -0.00010M |
| Change to liabilities | 0.00000M | -0.69176M | 0.02M | 0.26M | 1.38M |
| Total cashflows from investing activities | -2.28400M | -1.37146M | -0.83169M | -3.34223M | -4.13853M |
| Net borrowings | 4.59M | -0.20062M | 5.09M | 1.30M | 2.43M |
| Total cash from financing activities | 13.81M | 24.89M | 13.65M | 10.04M | 6.23M |
| Change to operating activities | - | 0.35M | -0.00148M | 0.02M | 0.03M |
| Net income | -32.78200M | -30.03097M | -30.77958M | -15.05438M | -16.75604M |
| Change in cash | -5.79600M | 1.14M | 3.25M | -3.59022M | -6.03437M |
| Begin period cash flow | 7.18M | 6.05M | 2.80M | 6.39M | 12.42M |
| End period cash flow | 1.39M | 7.18M | 6.05M | 2.80M | 6.39M |
| Total cash from operating activities | -17.30600M | -22.37792M | -9.62158M | -10.16696M | -8.17331M |
| Issuance of capital stock | 9.96M | 26.53M | 12.47M | 9.84M | 3.92M |
| Depreciation | 1.95M | 0.85M | 0.35M | 0.40M | 0.04M |
| Other cashflows from investing activities | - | - | - | - | -0.42598M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 0.29M | 0.88M | -1.54940M | -0.44262M |
| Change to account receivables | -0.19600M | 0.47M | 1.06M | -0.35688M | -0.00979M |
| Sale purchase of stock | -0.62200M | -1.43419M | -1.72220M | -0.29125M | - |
| Other cashflows from financing activities | 4.74M | -1.37146M | 4.90M | 12.52M | 2.31M |
| Change to netincome | 13.53M | 6.39M | 18.84M | 6.11M | 7.59M |
| Capital expenditures | 0.35M | 0.45M | 0.43M | 3.34M | 7.36M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | - | - | - | - | - |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | - | - | - | - | - |
| Free cash flow | -0.34800M | -0.45431M | -0.42915M | -3.34223M | -7.35933M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COPHF Creso Pharma Limited |
- -% | 0.12 | - | - | 0.41 | 0.31 | 1.01 | -0.2537 |
| ZTS Zoetis Inc |
0.38 0.20% | 191.09 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.17 0.45% | 37.27 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
8.28 4.48% | 193.00 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.12 0.81% | 14.70 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Melodiol Global Health Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and other health in Europe, Canada, the Asia Pacific, the United States, and internationally. The company develops and commercializes therapeutic products; develops and sells beauty and personal care products under the Green Goo, Southern Butter, and Goodgoo brands; and cultivates, processes, and sells cannabis products. Its products include cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and minerals in a lozenge delivery system; the ImpACTIVE Pro Releaf Stick to provide relief to muscle aches, particularly in professional sport, and acts as an alternative to pharmacological solutions sold through online channels; Ritual Green, a dried flower; Ritual Sticks for pre-rolled joints; and Ritual Gold, a handheld vapouriser. In addition, the company develops Halucenex, which is in phase II clinical trials, which will test the efficacy of psilocybin on treatment of resistant Post Traumatic Stress Disorder. Further, it engages in marketing of its hemp based food, feed supplements, and topical products; manufacture and sale of packaged consumer products; conducts clinical trial and development of synthetic psilocybin micro and macro dose formulations to treat treatment resistant depression and anxiety; and development of psychedelic medicines. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Health Limited in June 2023. Melodiol Global Health Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.
145 Stirling Highway, Nedlands, WA, Australia, 6009
| Name | Title | Year Born |
|---|---|---|
| Mr. Boaz Wachtel M.A., M.D., MBA | Co-Founder & Non-Exec. Chairman | 1960 |
| Mr. Christopher Grundy | Chief Financial Officer | NA |
| Mr. William Lay B.Com. | Group CEO, MD & Director | NA |
| Dr. Gian Trepp | Commercial & Marketing Director | NA |
| Ms. Micheline MacKay B.Sc., M.Sc., P.M.P. | MD & Exec. Director | NA |
| Ms. Jodi Scott | Exec. Director & Pres of US Operations | NA |
| Ms. Erlyn Saromines Dawson A.C.I.S., ACIS, AGIA, B.Com., BCom., GradDipACG | Joint Company Sec. | NA |
| Mr. Winton William Willesee C.P.A., GAICD, MAICD, MCom | Joint Company Sec. | 1970 |
| Dr. Simon H. W. Buckingham | Consultant | 1962 |
| Hon. Brian Walker | Strategic Consultant & Chair of Scientific Advisory Committee | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...